#183 : The Use of Follitropin-Delta in Indonesia: Current Evidence and Development

Abstract

Background and Aims: The current success of IVF treatments was aided by the fulminant ascent of recombinant DNA technologies. Follitropin delta (FD) is used to promote ovarian follicular proliferation. This research was aimed to investigate the current evidence and development of follitropin delta in its novel in Indonesia. Method: This prospective cohort study was conducted at the Yasmin IVF Center, Dr. Cipto Mangunkusumo General Hospital Jakarta from January 2021 to October 2022. All IVF/ICSI cycles in which follitropin delta (RekovelleⓇ, FE 999049; Ferring Pharmaceuticals, St. Prex, Switzerland) was used for ovarian stimulation. The outcome data were collected, including initial dose, and total dose of follitropin delta, retrieved oocytes, fertilized eggs, blastocyst day 3-5, embryo transfer, clinical pregnancy rates, and clinical implantation rates. The collected patients’ data (n = 20) who underwent IVF and received follitropin delta ovarian stimulation were divided into 2 groups by age (under 35 years and above 35 years). Results: The average oocyte, blastocyst, and embryo day 3 obtained in the study sample were higher in women under 35 years old. The pregnancy rate was higher in group 1 (33,30% vs. 25,0%) which was assessed based on a positive b-HCG results and a P4 value after receiving FET. Patients who followed follitropin delta ovarian stimulation had a pregnancy rate of 30%. Follitropin delta can be used in patients to successfully obtain a pregnancy in both groups, as it achieves higher result in women under 35 years old (33.3% vs. 25%). Conclusion: Optimizing ovarian response in IVF by using a program of follitropin delta dose achieved considerable rise in the quantity of good-quality, usable blastocysts. Assessing follitropin delta in individualized protocols and improving understanding of the dosages can help clinicians in evaluating follitropin delta in their conventional protocols.